Association of germline variation with the survival of women with BRCA1/2 pathogenic variants and breast cancer
Gabriel Wagner; Carl Blomqvist; Melissa C. Southey; Antonis C. Antoniou; Georgia Chenevix-Trench; Kristiina Aittomäki; Conxi Lazaro; Taru A. Muranen; Anna Jakubowska; Susan Slager; Eric Hahnen; Penny Soucy; Joe Dennis; Barbara Wappenschmidt; Rita K. Schmutzler; Judy Garber; Jacques Simard; Irene L. Andrulis; Goska Leslie; Marjanka K. Schmidt; Katherine L. Nathanson; Mads Thomassen; Christian F. Singer; Rainer Fagerholm; Caroline Maria Rossing; Drakoulis Yannoukakos; Sofia Khan; Paul James; Manuel R. Teixeira; Susan M. Domchek; Amanda B. Spurdle; kConFab Investigators; Maartje J. Hooning; HEBON Investigators; Michael T. Parsons; Julie M. Cunningham; Lesley McGuffog; Inge Sokilde Pedersen; Marc Tischkowitz; Douglas F. Easton; Heli Nevanlinna; Esther M. John; Jeffrey N. Weitzel; SWE-BRCA Investigators
Association of germline variation with the survival of women with BRCA1/2 pathogenic variants and breast cancer
Gabriel Wagner
Carl Blomqvist
Melissa C. Southey
Antonis C. Antoniou
Georgia Chenevix-Trench
Kristiina Aittomäki
Conxi Lazaro
Taru A. Muranen
Anna Jakubowska
Susan Slager
Eric Hahnen
Penny Soucy
Joe Dennis
Barbara Wappenschmidt
Rita K. Schmutzler
Judy Garber
Jacques Simard
Irene L. Andrulis
Goska Leslie
Marjanka K. Schmidt
Katherine L. Nathanson
Mads Thomassen
Christian F. Singer
Rainer Fagerholm
Caroline Maria Rossing
Drakoulis Yannoukakos
Sofia Khan
Paul James
Manuel R. Teixeira
Susan M. Domchek
Amanda B. Spurdle; kConFab Investigators
Maartje J. Hooning; HEBON Investigators
Michael T. Parsons
Julie M. Cunningham
Lesley McGuffog
Inge Sokilde Pedersen
Marc Tischkowitz
Douglas F. Easton
Heli Nevanlinna
Esther M. John
Jeffrey N. Weitzel; SWE-BRCA Investigators
NATURE PUBLISHING GROUP
Julkaisun pysyvä osoite on:
https://urn.fi/URN:NBN:fi-fe2021042826657
https://urn.fi/URN:NBN:fi-fe2021042826657
Tiivistelmä
Germline genetic variation has been suggested to influence the survival of breast cancer patients independently of tumor pathology. We have studied survival associations of genetic variants in two etiologically unique groups of breast cancer patients, the carriers of germline pathogenic variants in BRCA1 or BRCA2 genes. We found that rs57025206 was significantly associated with the overall survival, predicting higher mortality of BRCA1 carrier patients with estrogen receptor-negative breast cancer, with a hazard ratio 4.37 (95% confidence interval 3.03-6.30, P=3.1x10(-9)). Multivariable analysis adjusted for tumor characteristics suggested that rs57025206 was an independent survival marker. In addition, our exploratory analyses suggest that the associations between genetic variants and breast cancer patient survival may depend on tumor biological subgroup and clinical patient characteristics.
Kokoelmat
- Rinnakkaistallenteet [19207]